医药互动模式下注射用奥马珠单抗的合理用药分析  

Analysis of rational use of omalizumab for injection by using the doctor-pharmacist interaction model

作　　者：李博宇[1] 于晓佳[1] 张翼 陈罡[1] 黄克武[2] 安卓玲[1] LI Bo-yu;YU Xiao-jia;ZHANG Yi;CHEN Gang;HUANG Ke-wu;AN Zhuo-ling(Department of Pharmacy,Beijing Institute of Respiratory Medicine,Beijing Chao-Yang Hospital,Capital Medical University,Beijing 100020,China;Department of Respiratory and Critical Care Medicine,Beijing Institute of Respiratory Medicine,Beijing Chao-Yang Hospital,Capital Medical University,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院-北京市呼吸疾病研究所药事部,北京100020 [2]首都医科大学附属北京朝阳医院-北京市呼吸疾病研究所呼吸与危重症医学科,北京100020

出　　处：《临床药物治疗杂志》2023年第7期56-59,共4页Clinical Medication Journal

基　　金：北京市医院管理中心青年职工创新梦工场经费资助(202108);北京市呼吸疾病研究所“院所融合发展项目”(ysrh2022017)。

摘　　要：目的 分析注射用奥马珠单抗的使用情况,并提出改进和防范举措,促进合理用药。方法 通过医院信息系统收集2020年12月至2022年3月首都医科大学附属北京朝阳医院门诊使用注射用奥马珠单抗的处方记录,依据医药互动模式制订奥马珠单抗合理用药点评路径,从用药指征、用法用量和其他不适宜3个维度开展处方点评。结果 共收集2818条使用注射用奥马珠单抗的处方记录,涉及355例患者的就诊信息,主要诊断均为支气管哮喘。通过处方点评发现,注射用奥马珠单抗存在不合理用药17例(4.79%),均为无适应证用药,即不符合将奥马珠单抗用于大剂量吸入性糖皮质激素,并联合长效β2受体激动剂等其他控制药物治疗后症状仍未得到控制,且血清总IgE水平升高的重度过敏性哮喘患者;注射用奥马珠单抗起始用药剂量和使用频次均按药品说明书要求,且给药途径及其他均未见不合理。结论 医药互动模式下的合理用药点评可以更好地促进注射用奥马珠单抗在哮喘患者中的合理使用。Objective To analyze the use of omalizumab for injection,and promote its rational use by improving and preventing unreasonable issues.Methods The prescriptions of omalizumab for injection in the outpatient department of Beijing Chao-Yang Hospital,Capital Medical University from December 2020 to March 2022 were obtained through the hospital information system.According to the evaluation path of rational drug use of omalizumab under the doctor-pharmacist interaction model,the evaluation of rational drug use was carried out from three dimensions which were drug use indication,usage dosage and other inappropriate points.Results A total of 2818 prescription records using omazumab for injection were collected,involving 355 patients' medical information,with the main diagnosis being bronchial asthma.Through the prescription review,there were 17 cases with irrational drugs use(4.79%),which were all without indications.That is,it did not conform to the use of omalizumab in the treatment of patients with severe allergic asthma who had inhaled large doses of ICS and were treated with LABA and other control drugs,but the symptoms were not controlled,and the serum total IgE level was increased.The initial dosage and frequency of use of omalizumab for injection were in accordance with the requirements of the medication package insert,and no irrationality about the route of administration and others unreasonable situations was found.Conclusion Prescription review under the medical interaction mode can better promote the rational use of omalizumab for injection in asthmatic patients.

关 键 词：医药互动模式 注射用奥马珠单抗 合理用药 处方点评 

分 类 号：R969.3[医药卫生—药理学]